Charles River Labs said first-quarter earnings rose and it's raising its full-year outlook. The company also entered into an agreement with Elliott Investment Management and said it would conduct a review of its business.

BEVERLY HILLS (Reuters) -Pharmaceutical company Charles River Laboratories has reached a settlement with activist investor Elliott Investment Management to add four new directors to its board and launch a strategic review of the business, two sources familiar with the matter said.